- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | bioAffinity Technologies meldet Eigentümerwechsel bei Village Oaks Pathology | 2 | Investing.com Deutsch | ||
| 19.12.25 | bioAffinity Technologies vertagt außerordentliche Hauptversammlung mangels Quorum | 2 | Investing.com Deutsch | ||
| 19.12.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | bioAffinity Technologies: EPS verfehlt Schätzungen um 4,65 $ - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 14.11.25 | bioAffinity Technologies GAAP EPS of -$4.74, revenue of $1.45M | 1 | Seeking Alpha | ||
| 14.11.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | bioAffinity reports 111% increase in lung cancer test volume | 4 | Investing.com | ||
| 05.11.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10.25 | bioAffinity receives Australian patent acceptance for lung disease test | 2 | Investing.com | ||
| 28.10.25 | bioAffinity erhält australische Patentzusage für Test zur Lungengesundheit | 1 | Investing.com Deutsch | ||
| 28.10.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10.25 | Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains? | 8 | Benzinga.com | ||
| 16.10.25 | bioAffinity stock soars after receiving patent allowance for AI lung cancer test | 1 | Investing.com | ||
| 16.10.25 | Patent für KI-Lungenkrebstest beflügelt bioAffinity-Aktie | - | Investing.com Deutsch | ||
| 15.10.25 | bioAffinity Technologies, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 15.10.25 | Biotechnology company bioAffinity regains compliance with Nasdaq's continued listing rules | 4 | Seeking Alpha | ||
| 15.10.25 | bioAffinity Technologies erfüllt wieder Nasdaq-Anforderungen | 2 | Investing.com Deutsch | ||
| 09.10.25 | bioAffinity Technologies schließt registrierte Direktplatzierung über 1,8 Millionen US-Dollar ab | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,375 | -4,09 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,560 | -3,58 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,310 | +1,85 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,795 | -1,85 % | Onco-Innovations Limited: Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care | VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce, further to its... ► Artikel lesen | |
| NEOVACS | 0,007 | -1,33 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| CYBIN | 6,250 | +0,81 % | Cybin Inc (2): Cybin starts trading on Nasdaq | ||
| BIOLINERX | 2,240 | -18,69 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| BIOARCTIC | 31,060 | -0,45 % | BioArctic: BLA for subcutaneous formulation of Leqembi accepted in China | STOCKHOLM, Jan. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation... ► Artikel lesen | |
| NUCANA | 3,600 | -0,55 % | NuCana plc: NuCana Appoints Theresa Bruce as Chief Operating Officer | EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes... ► Artikel lesen | |
| GENSIGHT BIOLOGICS | 0,093 | +3,67 % | GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates | Cash position amounted to €2.4 million as of December 31, 2025
Successful closing of fundraising worth nearly €2.9 million on January 7, 2026
Payments for early access treatments... ► Artikel lesen | |
| IMMUNOME | 20,450 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| PEPGEN | 6,740 | -5,60 % | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 294,38 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| APOGEE THERAPEUTICS | 77,48 | -1,85 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,830 | +0,73 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen |
BIOAFFINITY TECHNOLOGIES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,78 % bei einem Aktienkurs von 1,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.